To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

No Significant Differences in Blood Loss or Clinical Outcomes with IA-TXA in ACL Reconstruction

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
August 2020

No Significant Differences in Blood Loss or Clinical Outcomes with IA-TXA in ACL Reconstruction

Vol: 9| Issue: 8| Number:18| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Intra-articular Administration of Tranexamic Acid Has No Effect in Reducing Intra-articular Hemarthrosis and Postoperative Pain After Primary ACL Reconstruction Using a Quadruple Hamstring Graft: A Randomized Controlled Trial.

Orthop J Sports Med. 2020 Jul; 8(7): 2325967120933135.

Contributing Authors:
JW Lee SG Kim SH Kim HW Cho JH Bae

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty patients scheduled for an anterior cruciate ligament (ACL) reconstruction for the treatment of an ACL tear were randomized to receive an intra-operative intra-articular injection of tranexamic acid (TXA) or no treatment. The primary outcome of interest was blood loss, calculated using hemoglobin levels. Secondary outcomes of interest included pain on a Visual Analog Scale (VAS), patellar cir...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue